Keeping a strong focus on theranostics of GRPR-positive cancer, we limit this review to peptide analogs labeled with diagnostic or therapeutic radiometals, excluding the F-18 analogs suitable for PET imaging only. The gene discussed is GRPR; the disease is cancer.